Using cardio-metabolomic diagnosis to reduce the consequences of obesity Read more about Using cardio-metabolomic diagnosis to reduce the consequences of obesity
ORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount Sinai Read more about ORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount Sinai
Our researcher in oncology, Gema Malet, receives a Marie Skłodowska-Curie research grant Read more about Our researcher in oncology, Gema Malet, receives a Marie Skłodowska-Curie research grant
IUL launches iPeak+, the new lateral flow reader for rapid tests Read more about IUL launches iPeak+, the new lateral flow reader for rapid tests
ORYZON publishes vafidemstat first-in-human clinical trial manuscript in CNS Drugs journal Read more about ORYZON publishes vafidemstat first-in-human clinical trial manuscript in CNS Drugs journal
ORYZON to participate in upcoming virtual international conferences in March and April Read more about ORYZON to participate in upcoming virtual international conferences in March and April
ORYZON announces successful pre-IND meeting with FDA for the clinical development of vafidemstat in Borderline Personality Disorder Read more about ORYZON announces successful pre-IND meeting with FDA for the clinical development of vafidemstat in Borderline Personality Disorder
ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the virtual AD/PD-2021 conference Read more about ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the virtual AD/PD-2021 conference
Drug Developers Can Measure ADCC in Biologically Relevant Systems with New Promega Bioluminescent Primary Cell Bioassay Read more about Drug Developers Can Measure ADCC in Biologically Relevant Systems with New Promega Bioluminescent Primary Cell Bioassay
